Akari Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: AKTX · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1541157
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: AKTX
TL;DR
Akari Therapeutics (AKTX) filed an 8-K on 3/2/25 detailing a material definitive agreement and equity sales.
AI Summary
Akari Therapeutics Plc announced on March 2, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing details are associated with accession number 0001193125-25-043544.
Why It Matters
This 8-K filing indicates significant corporate activity for Akari Therapeutics, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can carry inherent risks related to deal terms and dilution.
Key Numbers
- 001-36288 — SEC File Number (Akari Therapeutics' SEC filing identifier)
- 98-1034922 — I.R.S. Employer Identification No. (Akari Therapeutics' tax identification number)
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- 0001193125-25-043544 (accession_number) — Filing identifier
- March 2, 2025 (date) — Date of earliest event reported
- 22 Boston Wharf Road FL 7 Boston, MA 02210 (address) — Principal Executive Offices
- Celsus Therapeutics Plc. (company) — Former company name
- Morria Biopharmaceuticals PLC (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Akari Therapeutics?
The filing states that Akari Therapeutics entered into a 'Material Definitive Agreement' but does not provide specific details about the agreement's terms or parties involved in this section of the report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 2, 2025.
What are the principal executive offices of Akari Therapeutics?
The principal executive offices of Akari Therapeutics are located at 22 Boston Wharf Road, FL 7, Boston, MA 02210.
Has Akari Therapeutics undergone any previous name changes?
Yes, Akari Therapeutics was formerly known as Celsus Therapeutics Plc. and prior to that, Morria Biopharmaceuticals PLC.
What are the key items reported in this 8-K filing?
This 8-K filing reports on the entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, and Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding Akari Therapeutics Plc (AKTX).